Are adults who have bipolar disorder depression medicated with Lurasidone more likely to have a better tolerability compared to those treated with Risperidone?” Title/Study Patient Age Intervention Dose Comparator Outcome Measurement

Are adults who have bipolar disorder depression medicated with Lurasidone more likely to have a better tolerability compared to those treated with Risperidone?”
Title/Study Patient Age Intervention Dose Comparator Outcome Measurement
Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study – 2016_https://www.ncbi.nlm.nih.gov/pubmed/26552942 Both N/A Treatment with Lurasidone shows a reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores in mixed feature group 20-60 mg/d Placebo
Health-related quality life among patients with lurasidone: results from a switch trial in patients with schizophrenia – 2014_https://www.ncbi.nlm.nih.gov/pubmed/24559217_PUBMED ID_ 24559217 Both Adults preswitch antipsychotic, significant improvements in PETiT total scores were observed in patients. switched from quetiapine, risperidone, aripiprazole, and ziprasidone 40 mg/d and 80 mg/d and the from 40-120 mg/d switched from quetiapine, risperidone, aripiprazole, and ziprasidone health-related quality of life (HRQoL) following the switch to Lurasidone measured by PETiT domain scores
Effect of lurasidone on meaningful change in health-related quality of life patients with bipolar depression – 2016_https://www.ncbi.nlm.nih.gov/pubmed/?term=26717493_PMID: 26717493 Both Adults achieved a clinically meaningful improvement in health-related quality of life (HRQoL) as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire 20-60 mg/day or 80-120mg/day Lurasidone and Placebo significantly higher proportion of lurasidone-treated patients reported a clinically meaningful improvement in HRQoL versus placebo in monotherapy Clinical Global Impression-Severity, Bipolar Version (CGI-BP-S) scale
Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study_2012_https://www.ncbi.nlm.nih.gov/pubmed/22395527_PMID: 22395527 – http://resolver.ebscohost.com.proxy.libraries.rutgers.edu/openurl?sid=EBSCO%3aedselc&genre=article&issn=02681315&ISBN=&volume=27&issue=3&date=20120501&spage=165&pages=165+-+176&title=International+Clinical+Psychopharmacology&atitle=Long-term+safety+and+tolerability+of+lurasidone+in+schizophrenia%3a+A+12-month%2c+double-blind%2c+active-controlled+study&aulast=Citrome%2c+L.&id=DOI%3a10.1097%2fYIC.0b013e32835281ef&site=ftf-live Both Adults 40-120 mg (L) and 2-6 mg ® Lurasidone and Risperidone evaluate the long-term safety and tolerability of lurasidone in the treatment of schizophrenia N/A

find the cost of your paper